News

The Company is pleased to announce its audited results for the year ended 31 December 2024.

Proteome Sciences (AIM: PRM) announces that the Company’s results for the year ending 31 December 2024 will be announced on 10 April 2025 (the “Final Results”). The Company looks forward to updating shareholders on the Company’s performance and on the outlook for 2025. 

On the 11 April 2025 at 10:30 BST the Company’s Executive Chairman, Christopher Pearce and Dr Ian Pike, the Chief Scientific Officer (CSO), will provide a live presentation relating to the Final Results via Investor Meet Company.

Proteome Sciences (AIM:PRM), is pleased to announce that the Company has secured a contract win from a US biopharmaceutical company using the Company’s mass spectrometry services for the analysis of samples for an on-going clinical trial. This project will be provided utilising the Good Clinical Laboratory Practice (“GCLP”) accreditation obtained by Proteome Sciences specifically for this type of project. 

The Board of Proteome Sciences is pleased to provide a trading update and announce that it has entered into new loan agreements with Vulpes Investment Management Private Limited (“Vulpes”) and Christopher Pearce (together the “Lenders”), for a total of £1 million (the “Loan Facility”), as well as an update on Board changes.  

Proteome Sciences announces its unaudited interim results for the six months ended 30 June 2024 (“H1 2024”).

The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 12.00 noon today, all resolutions were duly passed.

Annual General Meeting Statement

Proteome Sciences (AIM:PRM), is pleased to announce that the Company has secured a contract win from a US biopharmaceutical company using the Company’s mass spectrometry services for the analysis of samples for an on-going clinical trial.

The Company is pleased to announce its audited results for the year ended 31 December 2023.